Skip to main content

Table 1 Patient characteristics

From: Levels of serum biomarkers from a two-year multicentre trial are associated with treatment response on knee osteoarthritis cartilage loss as assessed by magnetic resonance imaging: an exploratory study

  Chondroitin sulfate (n = 57) Celecoxib (n = 62) P value
Male, n (%) 26 (46) 29 (47) 0.899*
Age, years 61 ± 8 61 ± 8 0.909
Body mass index, kg/m2 30.3 ± 6.42 32.5 ± 5.9 0.020
Synovial membrane thickness, mm 1.04 ± 0.23 1.01 ± 0.22 0.528
Bone marrow lesion, score 2.49 ± 3.20 2.63 ± 2.33 0.291
Synovial fluid volume, mL 14.8 ± 15.9 11.2 ± 12.3 0.210
Joint swelling and effusion, n (%) 37 (65) 32 (52) 0.142*
Pain VAS, mm 60.6 ± 15.9 57.2 ± 18.6 0.252
WOMAC
 Total score (0–240) 121 ± 38 120 ± 46 0.934
 Pain score (0–50) 24 ± 8 24 ± 9 0.909
 Stiffness score (0–20) 11 ± 4 11 ± 4 0.694
Physical function score (0–170) 86 ± 29 85 ± 34 0.842
Quality of life (SF-36)
 Physical component summary 36.31 ± 7.82 36.33 ± 8.13 0.610
Cartilage volume (mm3)    
Medial
 Compartment 4586 ± 1517 4324 ± 1309 0.445
 Condyle 2881 ± 1020 2682 ± 833 0.448
 Plateau 1705 ± 545 1642 ± 532 0.529
  1. Data shown are number of patients (%) or mean ± SD. Continuous variables were compared using the Student's t test/Mann-Whitney test; p values in italics are statistically significant. *Proportions were compared using the chi-squared test/Fisher’s exact test. VAS visual analog scale, WOMAC Western Ontario and McMaster Universities Osteoarthritis Index, SF-36 Short Form 36